Mer­ck KGaA beefs up its mR­NA work with a $780M buy­out of a boom­ing play­er

Burst­ing at the seams and ex­e­cut­ing plans for swift ex­pan­sion to sup­port its man­u­fac­tur­ing work for the mR­NA vac­cine out of Pfiz­er/BioN­Tech, In­di­anapo­lis-based Ex­e­lead has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER